局部晚期甲状腺癌分子靶向药物治疗临床疗效及安全性分析

目的 探讨分子靶向药物治疗在局部晚期甲状腺癌中的临床疗效及安全性。方法 回顾性收集2020年4月至2023年4月于四川大学华西医院采用分子靶向药物治疗的91例局部晚期甲状腺癌患者的临床资料，使用实体肿瘤的疗效评价标准1.1版(RECIST 1.1)评估分子靶向药物的临床疗效，使用不良事件通用术语评价标准5.0版(CTCAE5.0)评估分子靶向药物治疗的不良反应，应用Kaplan-Meier法计算患者2年生存率并绘制生存曲线。结果 91例患者客观缓解率(ORR)和疾病控制率(DCR)分别为12.09%(11/91)和80.22%(73/91),2年总生存率和无疾病进展生存率分别为83.52%(95%CI:0.76～0.91)和72.53%(95%CI:0.60～0.85)。治疗相关3级不良反应发生率：手足综合征和疲劳均为4.40%,高血压、咽痛、蛋白尿、腹泻、谷丙转氨酶升高均为1.10%。未观察到因严重不良反应事件致治疗终止的病例发生。结论 分子靶向药物用于治疗局部晚期甲状腺癌患者总体疗效良好，药物的不良反应可控。

Clinical efficacy and safety analysis of molecular targeted drug therapy for locally advanced thyroid cancer

Objective To explore the clinical efficacy and safety of molecular targeted therapy in the treatment oflocally advanced thyroid carcinoma.Methods The clinical data of 91 patients with locally advancedthyroid carcinoma whoreceived molecular targeted therapy in West China Hospital,Sichuan University from April 2020 to April 2023 wereretrospectively collected.The clinical efficacy of molecular targeted therapy was assessed using the Response EvaluationCriteria in Solid Tumors version 1.1(RECIST 1.1).The adverse reactions of molecular targeted therapy was evaluated bythe Common Terminology Criteria for Adverse Events version 5.0(CTCAE5.0).UsingKaplan-Meier method to calculate the 2-year survival rate and plot the survival curve.Results By the last follow-upon April 30,2023,the objecive remission rate and diseasecontrol rate were 12.09%(11/91)and 80.2%(73/91),respectivly.The overall -yearsurvival rate and progresion-free survival ratewere 83.52%(95%CI:0.76-0.91)and 72.53%(95%CI:0.60-0.85),respectively.The incidence of treatment-related grade3 adversereactions were 4.40%of hand-foot syndrome and fatigue,1.10%of hypertension,proteinuria,diarrhea,andincreased alanine transaminase(ALT).No cases of molecular treatment termination due to severe adverse reactions wereobserved.Conclusion The efficacyof molecular targeted drugs for locally advanced thyroid carcinoma patientsis acceptable,with controllable toxicity